News Releases

Date Title and Summary Additional Formats
May 16, 2022 Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for
PDF Version
April 27, 2022 Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
PDF Version
March 28, 2022 Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
- Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 – REHOVOT, Israel and WILMINGTON, Del., March 28, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Ayala or the Company) (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing
PDF Version
March 9, 2022 Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
PDF Version
March 8, 2022 Ayala Pharmaceuticals, MD Anderson Cancer Center and the Adenoid Cystic Carcinoma Research Foundation Announce Initiation of Enrollment in Window of Opportunity Study of AL101 in Adenoid Cystic Carcinoma
Window of Opportunity Study is Evaluating AL101 Administered Prior to Surgery in Patients with Advanced, Notch-activated ACC REHOVOT, Israel and WILMINGTON, Del., March 08, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), together with M.D.
PDF Version
February 23, 2022 Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors
Interim Results expected mid-2022 REHOVOT, Israel and WILMINGTON, Del., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and
PDF Version
January 6, 2022 Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
PDF Version
January 4, 2022 Ayala Pharmaceuticals Announces Key Business Objectives for 2022
-- Data read-outs expected on AL102 in desmoid tumors and AL101 in ACC and TNBC -- REHOVOT, Israel and WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule
PDF Version